Perspectives on Regulatory T Cell Therapies | Zendy

Michaël Probst-Kepper | Zendy; Andrea Kr ouml ger | Zendy; Henk Garritsen | Zendy; Jan Buer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Perspectives on Regulatory T Cell Therapies

Author(s) -

Michaël Probst-Kepper,

Andrea Kr ouml ger,

Henk Garritsen,

Jan Buer

Publication year - 2009

Publication title -

transfusion medicine and hemotherapy

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000235929

Subject(s) - foxp3 , il 2 receptor , regulatory t cell , autoimmunity , effector , t cell , biology , adoptive cell transfer , immunology , chimeric antigen receptor , t cell receptor , computational biology , immune system

Adoptive transfer in animal models clearly indicate an essential role of CD4+ CD25+ FOXP3+ regulatory T (T(reg)) cells in prevention and treatment of autoimmune and graft-versus-host disease. Thus, T(reg) cell therapies and development of drugs that specifically enhance T(reg) cell function and development represent promising tools to establish dominant tolerance. So far, lack of specific markers to differentiate human T(reg) cells from activated CD4+ CD25+ effector T cells, which also express FOXP3 at different levels, hampered such an approach. Recent identification of the orphan receptor glycoprotein-A repetitions predominant (GARP or LRRC32) as T(reg) cell-specific key molecule that dominantly controls FOXP3 via a positive feedback loop opens up new perspectives for molecular and cellular therapies. This brief review focuses on the role of GARP as a safeguard of a complex regulatory network of human T(reg) cells and its implications for regulatory T cell therapies in autoimmunity and graft-versus-host disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research